On March 4, 2026, NeOnc Technologies Holdings, Inc. announced results from its Phase 1/2 clinical trial of NEO212 and held an investor conference call to discuss the findings. This event is significant for investors as it relates to the company's progress in developing a potentially impactful treatment.